Project Grant R41NS086115

Summary Yale University received a $3.31 million Cooperative Agreement from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, awarded on May 22, 2026, with completion scheduled for November 30, 2030. The award funds a double-blind, randomized, placebo-controlled clinical trial examining the efficacy and safety of intrathecal AXER-204 (a soluble Nogo receptor decoy)...

Federal Project Grant Award Summary Drexel University received a $228,688 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective June 15, 2026 through March 31, 2028. The award funds research to develop and test a novel intrabody-based therapeutic approach for Hereditary Spastic Paraplegia 4 (SPG4-HSP), a neurodegenerative disorder caused...

Spinethera Inc. was awarded a $4,970,750.90 Project Grant from the Defense Health Agency to conduct GLP toxicology testing and Phase 2/3 development for a nonopioid, injectable drug product for the treatment of lumbosacral radiculopathy, also known as sciatica. This work will be carried out under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform military and public health care through innovative and impactful investigations....

Federal Grant Award Summary Wake Forest University Health Sciences received a $502,528 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop next-generation protein neurotherapeutics for botulism poisoning. The award, effective June 1, 2026, through May 31, 2028, funds research to create novel antidote candidates targeting botulinum neurotoxins (BoNTs), which are classified as...

Summary of Federal Project Grant Award Renerva, Inc. received a $500,000 project grant award from the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279) for the period of September 1, 2025 through August 31, 2026. The company is developing PNM-CAP (Peripheral Nerve Matrix-Cap), a biodegradable nerve capping device designed to prevent painful neuroma formation following extremity amputations. The device, derived from porcine...

This federal Cooperative Agreement award, totaling $1,594,319.00, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Texas Health Science Center at Houston (UTHealth). The award aims to develop and test an innovative, non-invasive device called Breathing-Controlled Electrical Stimulation (BREESTIM) for the management of neuropathic pain after spinal cord injury. The project...

Federal Project Grant Award Summary Award Details: Alcamena Stem Cell Therapeutics, LLC received a $3.0 million Project Grant from the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded August 7, 2025, with completion targeted for July 31, 2027. Products and Services: The award funds Phase 1 development and clinical advancement of ASCT-83, a novel, first-in-class cell and tissue-permeable peptide therapeutic...

The Spinex Inc. was awarded a $4,719,091 Project Grant from the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases to develop and clinically validate a transcutaneous electrical spinal cord neuromodulation (TESCON) device to mitigate symptoms of neurogenic bladder resulting from spinal cord injury. The award, made under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support Spinex in building a commercial...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $3,565,780 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a groundbreaking high-frequency trans-spinal magnetic stimulation (HF-TSMS) system for the non-invasive treatment of neuropathic pain. The funded project aims to create an HF-TSMS tool that can target neural pathways involved in...

Federal Cooperative Agreement Summary The National Human Genome Research Institute awarded a $1,095,678 Cooperative Agreement to Boston Children's Hospital, effective September 20, 2025, through August 31, 2030, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program administered by the National Institute of Neurological Disorders and Stroke. This award funds the Spastic Paraplegia Centers of Excellence Research Network (SP-CERN) Rare...